CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
Memantine +1 moredrug
Likely dose
Memantine 10 mg orally twice dailyAI-extracted
Key inclusion· 7
  • Age ≥50 years and residing in the community
  • Probable Alzheimer's disease diagnosed by DSM-IV and NINCDS-ADRDA criteria
  • CT or MRI brain scan and medical workup compatible with AD diagnostic criteria
  • MMSE score 3–14
Key exclusion· 6
  • Non-English speaking patient and/or caregiver
  • Dementia due to conditions other than Alzheimer's disease
  • Vascular dementia or modified Hachinski Ischemic Rating scale >4
  • Major depressive disorder

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00120874
NCT00120874Phase 4Completed

Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial

NYU Langone Health·interventional·Posted Jul 19, 2005·Updated Oct 25, 2016

In Brief

A Phase 4 clinical trial evaluating Individualized management of AD including caregiver training and Memantine for Alzheimer's Disease. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 19, 2005
Enrollment StartAug 1, 2006
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 21.0 years ago

Interventions

Individualized management of AD including caregiver trainingbehavioral

Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.

Memantinedrug

Patients receive 10 milligrams of memantine twice daily.